Ken Griffin Enlivex Therapeutics Ltd. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 16,100 shares of ENLV stock, worth $19,642. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,100
Previous 200
7950.0%
Holding current value
$19,642
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding ENLV
# of Institutions
24Shares Held
2.13MCall Options Held
16.1KPut Options Held
3.4K-
Armistice Capital, LLC New York, NY1.7MShares$2.07 Million0.03% of portfolio
-
Morgan Stanley New York, NY245KShares$298,7680.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny71.7KShares$87,4600.0% of portfolio
-
Sigma Investment Counselors Inc30KShares$36,6000.0% of portfolio
-
Xtx Topco LTD London, X024.8KShares$30,2800.0% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $22.5M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...